Factor will deliver seven presentations, representing the company's most expansive presentation of data to date.
"2024 marks the fifth year that Factor will present our latest data at the Annual Meeting of the ASGCT," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "This year promises to be particularly exciting, as we present our progress on deploying the powerful mRNA cell-engineering technologies that we have built at Factor over the last decade."
Dr. Kyle Garland, Director of Translational Science at Factor, commented, "We have been working hard over the last year to address several critical needs in our industry, including tissue-targeted delivery of nucleic acids, durable allogeneic cell therapies, and effective approaches for targeting solid tumors. We look forward to presenting our results in these and other areas next month at the ASGCT Annual Meeting."
About Factor Bioscience
Founded in 2011, Factor Bioscience develops technologies for engineering cells to promote health and improve lives. Factor Bioscience is privately held and headquartered in Cambridge, MA.
For more information, visit www.factorbio.com.
